A subanalysis of a recent cohort efficacy trial of a pertussis vaccine was performed to determine its efficacy against cough illnesses due to Bordetella parapertussis infections. Infants received four doses of either the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis (DTaP) vaccine or the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis (DTP) vaccine at 3, 4.5, 6, and 15-18 months of age; controls received three doses of diphtheria and tetanus toxoids (DT) vaccine only. All subjects were prospectively followed for cough illnesses of §7 days' duration; cases of B. parapertussis infection were confirmed by positive culture, household contact, or serology. Seventy-six cough illnesses due to B. parapertussis were identified; 24 occurred in 929 DTaP recipients, 37 in 937 DTP recipients, and 15 in 321 DT recipients, resulting in an efficacy of 50% for DTaP vaccine (95% CI [confidence interval], 5% to 74%) and 21% for DTP vaccine (95% CI, 045% to 56%). The data in the present analysis suggest that the Lederle/Takeda DTaP vaccine but not the Lederle whole-cell component DTP vaccine has efficacy against B. parapertussis infection.
Pertussis is caused by Bordetella pertussis and, less freillnesses correlated inversely with study physician compliance with the study protocol regarding the monitoring of cough quently, by Bordetella parapertussis [1] . Although B. pertussis and B. parapertussis have a number of similar antigens, it illnesses [4] . In the group of highly compliant study physicians, we noted that the efficacy of the DTaP vaccine against is generally believed that diphtheria and tetanus toxoids and pertussis (DTP) vaccines do not prevent illness due to B. para-B. parapertussis was more clearly identified; these data are the subject of this report. pertussis infection [2] .
However, in our primary analysis of data from our recent cohort efficacy trial, in which the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and the Lederle Methods whole-cell component DTP vaccine were compared, we found
The methods relating to several analyses of our vaccine suggestive evidence that the DTaP vaccine but not the DTP efficacy trial have been previously presented in detail [3 -5] vaccine had efficacy against B. parapertussis cough illnesses and will therefore only be summarized herein. The study was [3] . Specifically, the point estimate of efficacy of DTaP against performed at 227 sites, which were mainly private pediatric laboratory-confirmed B. parapertussis cough illnesses of §7 office practices. This present analysis includes the findings at days' duration was 31%, but the lower bound of the 95% 59 of the most compliant practices, based on a reporting rate confidence interval was õ0%.
of cough illnesses of ú20% per year or a referral rate of ú10% In a recent substudy of our cohort efficacy trial, we found that efficacy of the DTaP vaccine against B. pertussis cough per year (see below). Healthy 2-to 4-month-old infants received three doses of DTaP or DTP at 6-to 8-week intervals and a fourth dose at of Health and Human Services and those of the authors' institutions were followed in the conduct of the study.
All cough illnesses of §7 days' duration in study subjects ing, or posttussive vomiting), 48 mild cases (63%) were removed from the data set: 16 (67%) of 24 among DTaP recipients, 23 (62%) of 37 among DTP recipients, and 9 (60%) persisted for §14 days, the subjects were to be referred to a of 15 among DT recipients. Point estimates of efficacy were central investigator from the central study center, who saw the marginally higher (DTaP, 58%; DTP, 25%) than were those patient and performed a standardized evaluation. Convalescentagainst B. parapertussis infection with cough of §7 days' phase blood samples were collected 6 -8 weeks after illness duration. onset. The follow-up period for cough illnesses started 2 weeks after the third vaccine dose in DTaP and DTP recipients (2 Discussion months after the second dose in DT recipients) and ended in December 1994.
For many decades, conventional whole-cell pertussis vacThe case definition for this analysis required one of the cines have been effective in preventing cough illnesses caused following: a cough illness of §7 days' duration and the isolaby B. pertussis [2] . Although efficacy of these vaccines against tion of B. parapertussis from the vaccinee or a household cough due to B. parapertussis has not previously been prospeccontact within 28 days of the cough onset in the vaccinee, or a tively studied, the past literature suggests that they had no significant rise in IgG or IgA titer to filamentous hemagglutinin, efficacy. Eldering and Kendrick [7] evaluated 55 children with pertactin, or fimbriae-2 (as determined by ELISA) in the ab-B. parapertussis infection, of whom 32 (58%) had a history of sence of evidence of B. pertussis infection (isolation of pertussis immunization; Borska and Simkovicova [8] diag-B. pertussis or a significant increase in IgG or IgA titer to nosed 173 children with B. parapertussis infection, and 95% pertussis toxin).
of them had previously been vaccinated against pertussis; fiThe DTaP vaccine was the Lederle/Takeda vaccine (Wyethnally, our group observed 82 children with B. parapertussis Lederle Vaccines and Pediatrics, Pearl River, NY), which coninfection with known immunization histories, and 25% had had tains 40 mg of pertussis protein with Ç86% filamentous hemagthree or more doses of pertussis whole-cell vaccine compared glutinin, 8% toxoided pertussis toxin, 4% pertactin, and 2% with only 4% of 165 age-matched children with B. pertussis fimbriae-2. The DTP vaccine (Wyeth-Lederle Vaccines and infection [9] . Moreover, there are numerous observations in Pediatrics) contained §4 protective pertussis units.
humans in which B. pertussis infection was followed by Vaccine efficacy was calculated by use of the Cox propor-B. parapertussis infection or vice versa, which served as argutional-hazards regression with SAS software (SAS Institute, ments for a lack of cross-protection between the two organisms Cary, NC) for personal computers [6] .
[10 -13]. Finally, in a murine respiratory model, neither filamentous hemagglutinin nor pertactin from B. pertussis, antigens that are very similar to B. parapertussis antigens, provided Results cross-protection against infection with B. parapertussis, whereas protection against B. pertussis occurred [14] . A total of 2,187 infants were enrolled at the 59 high-compliance physician offices (DTaP, 929; DTP, 937; DT, 321). The Since our present results are different from past clinical observations and laboratory studies, our findings need to be average reporting rate of cough illnesses was 21 per 100 person-years and the central investigator average referral rate was carefully scrutinized. Since most of our cases were established serologically without culture confirmation, it might be argued 15 per 100 person-years. During the follow-up period, 76 cough illnesses due to B. parapertussis infection occurred; these cases that these cases are in fact B. pertussis -induced illnesses and not B. parapertussis illnesses. In our cohort analysis, we found occurred in 24 DTaP, 37 DTP, and 15 DT recipients. The method of diagnosis according to vaccine group is presented that 10 (16%) of 64 subjects whose B. pertussis infections were documented by culture or by household contact did not have in NOTE. DTaP Å diphtheria and tetanus toxoids and pertussis, acellular pertussis component; DTP Å diphtheria and tetanus toxoids and pertussis, whole-cell pertussis component; DT Å diphtheria and tetanus toxoids (control).
* Vaccine efficacy was calculated by use of Cox proportional-hazards regression with SAS software (SAS Institute, Cary, NC) for personal computers. † Cases per 100 person-years.
